SIROCCO
Benralizumab in Severe Eosinophilic Asthma
Patient / Population Intervention / Exposure Comparison Outcome
In 1,205 patients with severe eosinophilic asthma on high-dose ICS/LABA, benralizumab 30 mg every 4 or 8 weeks reduced annual exacerbation rate compared with placebo.
N
1,205
Design
Multicentre phase-3 RCT
Endpoint
Annual exacerbation rate
Relevance
2
ResultExacerbation rate ratio 0.55 (95% CI 0.42–0.71) Q4W and 0.49 (0.37–0.64) Q8W, both p<0.0001; FEV1 improved.
Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127. 10.1016/S0140-6736(16)31324-1
Discussion & critique
With CALIMA, established benralizumab for severe eosinophilic asthma.